Reading CBD Labels: What FDA Approval Does—and Does Not—Mean

Rules checked: November 5, 2026. Laws and agency guidance can change. This is general information, not legal or medical advice.

Verified November 5, 2026. A CBD package can look reassuring without answering the question you actually have. “Lab tested” describes testing. “FDA registered” may refer to a facility. “Supplement Facts” is a label heading. None of those statements, on its own, means FDA approved the product.

The useful approach is to separate three questions: What is the product presented as? What exactly does the evidence cover? And what is the seller claiming it can do? This guide concerns those distinctions—not a nationwide retail permission slip. For the broader legal picture, see our federal and state CBD rules explainer.

Approval belongs to a particular drug, not CBD as a category

FDA drug approval is a specific regulatory decision about a product and its intended use. It involves evidence of safety and effectiveness and the ability to manufacture to federal quality standards. It does not mean an ingredient is harmless in every formulation or appropriate for every person.

The FDA cannabis FAQ identifies Epidiolex as the only FDA-approved drug containing CBD. This prescription medicine is approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients age one and older. Its approval does not transfer to a retail gummy, oil or cream containing CBD.

Nor is registration interchangeable with approval. FDA's approval explainer says establishment registration or drug listing does not itself establish approval or lawful marketing. A badge referring to a manufacturer's registration is not evidence that FDA reviewed the finished bottle.

Food, supplement and cosmetic labels follow different rules

Dietary supplements: FDA generally does not approve supplements before sale. Separately, its current CBD FAQ concludes that CBD products are excluded from the federal definition of a dietary supplement. Printing a Supplement Facts panel cannot, by itself, overcome that exclusion.

Conventional foods: FDA says introducing food with added CBD into interstate commerce is prohibited under the applicable statute. A Nutrition Facts panel does not resolve that problem. Hemp seed oil, hulled hemp seed and hemp seed protein powder are a different matter: FDA has evaluated GRAS notices for specified uses of these ingredients. That is not a general authorization to add CBD extract to food. “Hemp seed oil” and “CBD oil” should not be treated as synonyms.

Cosmetics: A moisturizer is not subject to the same premarket approval system as a new drug. FDA generally does not approve cosmetics or their labels before sale, with an exception for certain color additives. Products must nevertheless meet applicable safety and labeling requirements. According to FDA's cosmetic claims guidance, claims about treating disease or affecting body structure or function can make a product a drug, even if it also changes appearance.

These categories depend on more than a seller's chosen heading. Calling a product a cosmetic does not neutralize therapeutic claims elsewhere in its marketing.

A narrow 2026 policy is not general retail approval

There is an important qualification to sweeping statements about FDA enforcement. An FDA letter on medical research models, listed by its reading room as April 2026, describes conditional enforcement discretion for certain orally administered, hemp-derived CBD products.

It concerns specified drug-law provisions and products supplied through a qualifying Medicare-payable program under a treating physician's direction. Other conditions address supplement-style manufacturing and labeling, contamination, and marketing to children. This is not FDA product approval, a change to the supplement definition, or a blanket policy for ordinary retail CBD. A supplement-style panel alone does not establish that this narrow policy applies.

Likewise, FDA's January 26, 2023 call for a new regulatory pathway describes an agency recommendation—not an enacted general CBD authorization.

A certificate of analysis is evidence with boundaries

A certificate of analysis, or COA, can provide information about the sample tested. Its usefulness depends on what was measured and whether the report can be connected to the product in front of you.

As a practical document check, compare the product name and batch identifier with the report. Look for the laboratory, test date, units and listed analytes. A cannabinoid result does not automatically tell you whether pesticides, heavy metals or other contaminants were tested. A report marked “pass” is meaningful only in relation to the tests and limits it actually identifies.

Those are reading checks, not a complete legal checklist or a guarantee of quality. Even a matching report cannot prove clinical benefit, settle the product's legal category, approve its marketing claims or establish compliance everywhere it is sold. FDA's consumer update describes concerns about inaccurate CBD amounts and potentially unsafe contaminants. Laboratory information matters; it is not a substitute for the other questions.

Read the promise as carefully as the ingredient list

“Moisturizes skin” and “treats eczema” are not equivalent statements. The second presents a disease-treatment purpose. Similar issues arise when a seller claims a CBD product treats cancer or another disease. FDA's FAQ explains that therapeutic claims can bring drug requirements into play.

A disclaimer saying a statement has not been evaluated by FDA is not an approval mark. Nor does a generic disclaimer establish that an otherwise problematic CBD product or claim is lawful. Read the package alongside the product page, rather than treating the smallest print as the whole message.

For a non-medical label review, use this sequence:

• Identify the ingredient. Does the label specify CBD, hemp seed oil or an undefined hemp extract? Do not assume these mean the same thing.
• Identify the quantity. Distinguish milligrams per container from milligrams per listed portion, and CBD amount from the amount of an entire extract. This is arithmetic, not a dosing recommendation.
• Identify the evidence. Does the linked report match the batch, and what did it actually test?
• Identify the claim. Is the seller describing contents or promising a medical outcome? Does an approval claim identify an actual approved product?

No label review can establish that CBD is safe for an individual. FDA warns about risks including liver injury and drug interactions; personal health questions belong with a qualified healthcare professional.

Find more reporting in our US edition and learn how we handle verification and corrections in our editorial standards.

Sources and scope

Official sources below were freshly consulted November 5, 2026. This is general information, not medical advice, legal advice or a product recommendation. It does not evaluate a particular brand or replace state-specific requirements.

1. FDA: Cannabis and CBD questions and answers, especially questions 3–4, 9–12 and 17.
2. FDA: Is It Really “FDA Approved”?, approval, registration and product-category distinctions.
3. FDA: Cosmetics Labeling Claims, cosmetic versus drug claims.
4. FDA: Letter on Hemp-Derived Cannabidiol Products in Medical Research Models, April 2026 as identified in the FDA reading room.
5. FDA: Existing frameworks and a proposed new pathway, January 26, 2023.
6. FDA: What to know about cannabis-derived products, including CBD, quality concerns and safety limitations.